| pubmed-article:11306153 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11306153 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:11306153 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11306153 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:11306153 | lifeskim:mentions | umls-concept:C1412149 | lld:lifeskim |
| pubmed-article:11306153 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:11306153 | lifeskim:mentions | umls-concept:C1707491 | lld:lifeskim |
| pubmed-article:11306153 | lifeskim:mentions | umls-concept:C1318970 | lld:lifeskim |
| pubmed-article:11306153 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11306153 | pubmed:dateCreated | 2001-4-18 | lld:pubmed |
| pubmed-article:11306153 | pubmed:abstractText | ACTG (AIDS Clinical Trials Group) 384 is designed to evaluate different strategies for antiretroviral treatment in HIV-1-infected individuals with no previous exposure to antiretroviral treatment. The study is a randomized, partially double-blinded, controlled trial with 980 subjects at 81 centers in the United States and Italy. The study has a factorial design that addresses the following scientific questions: (1) Does the best initial choice of therapy include both a protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) in a four-drug combination with nucleoside analogue (NRTI) drugs, or should these agents be used sequentially in three-drug combinations?; (2) Which sequence is best in a three-drug regimen-PI followed by NNRTI or NNRTI followed by PI ?; (3) Which is the best sequence of dual NRTI combinations-zidovudine plus lamivudine followed by didanosine plus stavudine, or the converse? Subjects in the three-drug combination arms are offered a salvage regimen after failure of their second regimen; subjects in the four-drug combination arm are offered a salvage regimen after failure of their first regimen. The primary endpoint of the study is the time until salvage; secondary endpoints include time to virological failure and time to toxicity-related discontinuation of therapy. A Division of AIDS Data and Safety Monitoring Board will review the trial for safety and efficacy. Control Clin Trials 2001;22:142-159 | lld:pubmed |
| pubmed-article:11306153 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306153 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306153 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306153 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11306153 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306153 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11306153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306153 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11306153 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11306153 | pubmed:issn | 0197-2456 | lld:pubmed |
| pubmed-article:11306153 | pubmed:author | pubmed-author:ShaferR WRW | lld:pubmed |
| pubmed-article:11306153 | pubmed:author | pubmed-author:DeGruttolaVV | lld:pubmed |
| pubmed-article:11306153 | pubmed:author | pubmed-author:SmeatonL MLM | lld:pubmed |
| pubmed-article:11306153 | pubmed:author | pubmed-author:RobbinsG KGK | lld:pubmed |
| pubmed-article:11306153 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11306153 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:11306153 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11306153 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11306153 | pubmed:pagination | 142-59 | lld:pubmed |
| pubmed-article:11306153 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:meshHeading | pubmed-meshheading:11306153... | lld:pubmed |
| pubmed-article:11306153 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11306153 | pubmed:articleTitle | ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. | lld:pubmed |
| pubmed-article:11306153 | pubmed:affiliation | Center for Biostatistics in AIDS Research, Harvard School of Public Health, 651 Huntington Avenue, Francois-Xavier Bagnound Building, Boston, MA 02115-6017, USA. smeaton@sdac.harvard.edu | lld:pubmed |
| pubmed-article:11306153 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11306153 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11306153 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11306153 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11306153 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11306153 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11306153 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11306153 | lld:pubmed |
